Previous Close | 177,100.00 |
Open | 175,000.00 |
Bid | 173,200.00 x 0 |
Ask | 173,300.00 x 0 |
Day's Range | 171,000.00 - 175,400.00 |
52 Week Range | 131,000.00 - 241,000.00 |
Volume | |
Avg. Volume | 653,587 |
Market Cap | 36.633T |
Beta (5Y Monthly) | 0.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 500.00 (0.29%) |
Ex-Dividend Date | Dec 27, 2023 |
1y Target Est | N/A |
Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1] ZYMFENTRA is the first and only subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
Celltrion USA today announced that the company has submitted a Biologics License Application (BLA) for CT-P39, an interchangeable biosimilar candidate to XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA).[1]
Celltrion USA today announced the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CT-P47, a biosimilar candidate of the reference product ACTEMRA® (tocilizumab)[1].